KucukseymenSCagirciGBayarN. Which came first, the chicken or the egg? Paradox in peripheral arterial diseases. Angiology. 2018;69(1):83–84.
2.
KucukseymenSYukselIOArslanS. C-reactive protein is the origin for novel biomarkers. Angiology. 2016;68(6):562. doi:10.1177/0003319716685483.
3.
SignorelliSSAnzaldiMFioreV. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine. 2012;59(2):294–298.
4.
McDermottMMGuralnikJMCorsiA. Patterns of inflammation associated with the peripheral arterial disease. The InCHIANTi study. Am Heart J. 2005;150(2):276–281.
5.
VidulaHTianLLiuKCriquiMH. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008;148(2):85–93.
6.
KhandapourNJenningsBArmonMP. Do novel risk biomarkers reflect the severity of peripheral arterial disease?Angiology. 2011;62(2):126–123.
7.
LuoTLiJLiL. A study on the efficacy and safety assessment of propionyl-L carnitine tablets in treatment of intermittent claudication. Thromb Res. 2013;132(4):427–432.
8.
SignorelliSSFatuzzoPRapisardaF. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res. 2006;29(2):100–107.
9.
SignorelliSSFatuzzoPRapisardaF. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging. 2006;23(3):263–270.
10.
SignorelliSSNeriSDi PinoL. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Res Clin Pract. 2006;72(3):231–237.
11.
HiattWR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci. 2004;1033:92–98.
12.
SosinskaPBaurnEMackowiakB. Sulodexide reduces the proinflammatory effect of serum from patients with peripheral arterial disease in human arterial endothelial cells. Cell Physiol Biochem. 2016:40(5):1005–1012.
13.
DelaneyCLSparkJ. A randomized controlled trial of two supervised exercise regimens and their impact on inflammatory burden in patients with intermittent claudication. Vascular. 2016;24(3):264–272. doi: 10.1177/1708538115617622.
14.
SignorelliSSAnzaldiMLibraM. Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology. 2016;67(9):870–874.
